Safety and tolerability of nitric oxide given intermittently via inhalation to subjects with cystic fibrosis in a prospective open-label phase IIA trial

Authors
Category Primary study
JournalPediatr. Pulmonol.
Year 2014
This article has no abstract
Epistemonikos ID: d0a554f128d8cb5b5929d7585c82b7de73fe14cf
First added on: Jun 04, 2021